Biotech entity
pharma is the sole category represented across all 1 tracked stories. ADMA Biologics, Inc. is most often covered alongside ASCENIV, which appears in 1 of these 1 story. The tracked stories average 4 original sources each. ADMA Biologics, Inc. appears in 1 tracked Biotech story from July 12, 2026.
Last mentioned: Jul 12, 2026
Entity pulse
Coverage balance Negative coverage leads. Negative coverage exceeds positive coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
pharma is the sole category represented across all 1 tracked stories. ADMA Biologics, Inc. is most often covered alongside ASCENIV, which appears in 1 of these 1 story. The tracked stories average 4 original sources each. ADMA Biologics, Inc. appears in 1 tracked Biotech story from July 12, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 17 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering ADMA Biologics, Inc.. Shared-story counts are live from our verified record — not editorial picks.
Biotech firm ADMA Biologics faces securities fraud suit over alleged channel stuffing of ASCENIV, with Culper Research estimating real 2025 growth at -3% vs +20% reported.
ADMA Biologics, Inc. is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
